AMT Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted cell population targeting the human AMT gene within the A-549 lung adenocarcinoma epithelial cell line. This polyclonal knockout product provides a heterogeneous pool of edited cells, enabling loss-of-function analysis of aminomethyltransferase in a disease-relevant cancer background. Unlike a clonal isolate, the polyclonal configuration preserves cellular diversity, making it well-suited for pool-based functional genomics screens, bulk metabolomic profiling, and studies where population-level effects of AMT disruption are essential without the confounding influence of single-cell clonal selection artifacts.
The host cell line A-549 was derived from explanted lung tumor tissue of a 58-year-old Caucasian male with adenocarcinoma and has become a fundamental model in cancer biology, drug metabolism, and respiratory infection research. As an epithelial cell line, A-549 retains characteristic features of type II alveolar epithelium and is widely employed to investigate oncogenic signaling, tumor metabolism, and chemotherapeutic response. Its robust in vitro growth and extensive characterization in the literature make it an ideal chassis for introducing targeted genetic perturbations aimed at dissecting metabolic vulnerabilities in non-small cell lung cancer.
AMT encodes the T-protein of the mitochondrial glycine cleavage system, a multienzyme complex that catalyzes the oxidative decarboxylation of glycine. Mechanistically, AMT functions downstream of the P-protein (GLDC)?Cmediated decarboxylation step and interacts directly with the lipoic acid?Ccontaining H-protein (GCSH) to accept a methylene group. It then transfers this one-carbon unit to tetrahydrofolate, generating 5,10-methylenetetrahydrofolate and ammonia. This reaction is a crucial control point linking amino acid catabolism to one-carbon metabolism, feeding folate-dependent pathways including nucleotide synthesis and methylation reactions. AMT activity is regulated by substrate availability and mitochondrial one-carbon flux, and it operates in concert with pathway components such as DLD (dihydrolipoamide dehydrogenase), SHMT1 (serine hydroxymethyltransferase 1), and MTHFR (methylenetetrahydrofolate reductase).
In the context of A-549 lung adenocarcinoma cells, AMT disruption offers a powerful tool to interrogate the metabolic reprogramming that characterizes many cancers. Lung tumors often exhibit increased glycine consumption and dependence on one-carbon metabolism to sustain rapid proliferation. By knocking out AMT, researchers can investigate how the glycine cleavage system influences 5,10-methylenetetrahydrofolate pools, NADH production, and carbon dioxide release, thereby uncovering metabolic liabilities that may be exploited therapeutically. This model is particularly relevant for studying nonketotic hyperglycinemia (glycine encephalopathy) cellular pathology and for testing the efficacy of antifolate agents that target downstream biosynthetic pathways.
Typical experimental applications include quantitative assessment of glycine uptake and consumption via LC-MS metabolomics, evaluation of cell proliferation and clonogenic survival using colony formation assays, and analysis of mitochondrial function through Seahorse metabolic flux analysis. The knockout pool can also be used in RT-qPCR and Western blotting to verify pathway alterations and in apoptosis assays to gauge synthetic lethal interactions with chemotherapeutics. For additional information or technical support, please contact Ascent Research.
